Foresee Pharmaceuticals' Pediatric Drug Clinical Trial Receives Third Positive DSMB Recommendation

Foresee Pharmaceuticals announced on the 17th that its Phase III Casppian clinical trial has received a third consecutive positive recommendation from the Data and Safety Monitoring Board (DSMB), allowing the study to proceed without modifications according to the current clinical plan.